What are the opening hours?

Monday 09:00 - 17:00 Tuesday 09:00 - 17:00 Wednesday 09:00 - 17:00 Thursday 09:00 - 17:00 Friday 09:00 - 17:00

Liberia Medicines & Health Products Regulatory Authority, Mamba Point, Monrovia (2025)

01/08/2025

FOR IMMEDIATE RELEASE

LMHRA Clarifies Media Reports of Counterfeit Medication

PRESS RELEASE

Monrovia, Liberia—July 31, 2025: The attention of the Board of Directors and the Management of the Liberia Medicines & Health Products Regulatory Authority (LMHRA) has been drawn to recent trending media reports on a medical event that occurred at the St. Joseph’s Catholic Hospital in January 2025 and the resultant regulatory response of the LMHRA. While it is not standard practice of the LMHRA to litigate sensitive health issues in the media, it is expedient in this instance to lend some clarity on this matter.

Following the death of a 16-year-old boy at the St. Joseph’s Catholic Hospital in January 2025 and the subsequent release of the investigative report by the Liberia Medical & Dental Council (LMDC), the LMHRA launched an independent investigation into the medical products that were used in order to identify the cause(s) of the Adverse Drug Reaction (ADR), assess the regulatory status of the drugs involved, and proffer measures to prevent future occurrences.

The findings of the LMHRA’s independent investigation revealed that:

• The Anesthesia Bupivacaine spinal injection with the tradename Marcaine® Spinal Heavy (0.5%), in addition to five other medications, was administered to the patient

• Adverse Drug Reaction (ADR), which the patient experienced, is not uncommon in medical practice

• Attribution of ADR to a drug after a concoction of medications has been administered is rather inconclusive in the absence of further medical investigation, including testing.

• All of the medications administered during the procedure met the basic regulatory requirements as stipulated by the LMHRA with the exception of the Anesthesia Bupivacaine spinal injection

• The regulatory violation of the Bupivacaine spinal injection was that the labeling was done in a foreign language. This contravenes Chapter 2, section 1, number 3 of the regulations for the labelling of medicines and health products. It states that “all information contained on the label of medicines and health products must be in English.”

• In 2022, G2 Pharmacy applied to the LMHRA for the registration of Bupivacaine spinal injection and after the drug dossier review, were granted registration for a period of three years and has since been importing the drug into the country.

• The investigative team, on inspection of the pharmacy of St. Joseph Catholic Hospital noted that 24 packs of the anesthesia drug, Bupivacaine spinal injection, was still in stock and all had inscriptions in a foreign language.

After a review of the findings, the LMHRA Management Team carried out the following Regulatory actions:

• The remaining 24 packs of Bupivacaine spinal injection found in the St. Joseph Catholic Hospital Pharmacy were removed from the premise and taken to the LMHRA’s Central Office.

• The Regulatory lapses of G2 pharmacy relative to the labeling of the Bupivacaine spinal injection in a foreign language were referred to the LMHRA Hearing Board for further investigation

• The hearing Board, having done its investigation into the matter, recommended that G2 Pharmacy be fined the sum of US$10,000.00 (Ten thousand US Dollars) to which the G2 Pharmacy took an appeal. Having reviewed the Act of 2010 and the “Regulations on Mislabeling” and recognized that the recommended fine was far beyond the maximum fine for the offense, the management of LMHRA approved the appealed fine of $1,500.00 which the G2 Pharmacy has since paid.

• The Board of Directors also recommended that the LMHRA management team carry out the following actions:
o Conduct Post Market Surveillance to remove all Bupivacaine Spinal Injection in circulation.
o Plan and conduct refresher trainings for ADR reporters in health facilities
o Develop a Standard Operating Procedure (SOP) relative to the importation of drugs in small quantities (orphan products)
o Develop an information dissemination system that will promptly provide information on ADR to the general public.

The LMHRA assures the general public that it remains committed to its core mandate of protecting the health of the Liberian population by ensuring that only quality medicines and health products are in circulation in Liberia.

Signed: Momoh B. Siryon,
Communications Manager, LMHRA

22/07/2025

WAPCP Honors Dr. Bawo for Innovative Leadership

Monrovia, Liberia — July 22, 2025 — Dr. Luke L. Bawo, the esteemed Managing Director of the Liberia Medicines & Health Products Authority (LMHRA), has received a distinguished honor from the West Africa Postgraduate College of Pharmacists (WAPCP) in recognition of his groundbreaking contributions to Liberia’s pharmaceutical sector.
This award underscores Dr. Bawo’s unwavering dedication to advancing healthcare services and strengthening regulatory frameworks in Liberia, marking a pivotal milestone in his distinguished career.
The award was presented by Dr. Juwe Kercula, the President of the Pharmacists Association of Liberia PAL) and leading representative of the Liberia Chapter of WAPCP. Presenting the recognition, Dr. Kercula praised Dr. Bawo’s strategic leadership, vision, and relentless commitment to transforming Liberia’s pharmaceutical landscape. He emphasized that Dr. Bawo’s guidance has been crucial in implementing impactful regulatory reforms, improving access to safe medicines, and fostering an environment conducive to pharmaceutical innovation and quality assurance.
"Dr. Bawo’s leadership at LMHRA has been transformative," stated Dr. Kercula. "His efforts have significantly elevated the standards of pharmaceutical regulation, reinforcing Liberia’s dedication to public health and patient safety. Hence, WAPC is proud to recognize and support his exceptional contributions."
Under Dr. Bawo’s stewardship, he has spearheaded initiatives to streamline drug registration, improve quality assurance, and ensure adherence to international standards. His work has been vital in reducing the importation of substandard and falsified medicines and enhancing the capabilities of employees of the LMHRA.
Expressing gratitude for the acknowledgment, Dr. Bawo credited his team and partners for their collective efforts in advancing Liberia’s health objectives. He reaffirmed his commitment to strengthening regulatory systems, expanding access to quality medicines, and ensuring sustainable development within the pharmaceutical sector.
"This recognition reflects the hard work and collaboration of everyone at LMHRA and our health partners," Dr. Bawo said. "Our ongoing mission is to safeguard public health and position Liberia as a regional hub for safe, effective medicines."
This accolade not only celebrates Dr. Bawo’s visionary leadership but also highlights Liberia’s ongoing dedication to improving healthcare delivery and ensuring the safety and efficacy of medicines nationwide.
The Liberia Medicines & Health Products Authority (LMHRA) is the country’s primary regulatory body responsible for overseeing the registration, regulation, and supervision of medicines and health products. Its mission is to guarantee the safety, quality, and effectiveness of medicines available to the Liberian people.
The West Africa Postgraduate College of Pharmacists (WAPCP) is a professional organization dedicated to advancing pharmacy practice, education, and research across the West African region. Established to foster the development of highly qualified pharmacists, the college offers postgraduate training, certification, and continuous professional development opportunities to enhance expertise and leadership in pharmacy.

WAPCP aims to promote high standards of pharmaceutical practice, ensure the safe and effective use of medicines, and support the growth of pharmaceutical industries and healthcare systems in West Africa. The organization also facilitates collaboration among pharmacists, regulators, academic institutions, and healthcare professionals to address regional health challenges and improve public health outcomes.
By providing accreditation, specialized training programs, and forums for knowledge exchange, WAPCP plays a crucial role in strengthening pharmaceutical services and ensuring that pharmacists in the region are well-equipped to meet evolving healthcare needs.

15/07/2025

LMHRA, LMHPPP Hold Stakeholder Awareness on New Medicine Labeling

(Monrovia, July 15, 2025): The Liberia Medicines & Health Products Regulatory Authority (LMHRA), together with the Liberia Medicines & Health Product Protection Program (LMHPPP), recently hosted an important awareness session for key health sector stakeholders.

The event took place at the Ministry of Health’s conference room in Congo Town on Thursday, July 10, 2025. It drew regulators, civil society representatives, and dedicated Liberians from across the country, all committed to strengthening pharmaceutical safety and public health.

The main purpose of the meeting was to introduce an innovative medicine labeling system aimed at clearly differentiating between donor-supplied medicines and those bought commercially. This measure intends to prevent the misuse of humanitarian supplies and safeguard the integrity of medicines circulating in Liberia.

Dr. Luke Bawo, Managing Director of LMHRA, emphasized that the project supports Liberia’s broader development goals of transforming healthcare delivery by 2029. He explained that the initiative is part of a comprehensive plan to bolster regulatory systems, improve access to essential medicines, expand health insurance coverage, and modernize healthcare infrastructure—key steps toward a healthier, more equitable Liberia.

“Our goal extends beyond increasing access,” Dr. Bawo stated. “It’s about ensuring the quality of medicines. Our citizens deserve a health system that is safe, effective, and trustworthy.”

Dr. Michael Chu Nepay, Program and Planning Coordinator at LMHRA, provided details about the new labeling system, highlighting its use of advanced technology for product verification and traceability. He introduced the Kulinda-Liberia platform, a sophisticated management system that employs smart security labels with embedded barcodes and color indicators, allowing real-time monitoring and instant validation of medicines’ authenticity.

“This initiative not only enhances public health protection for Liberia but also aims to serve as a model for neighboring West African countries,” Dr. Nepay remarked. “As the global community observes, LMHPPP’s approach could set a regional standard.”

The meeting was also intended to clarify stakeholders’ roles. Dr. Sandra Nagbe from the Program & Planning Unit described the Comprehensive Authentication and Traceability Program as a nationwide effort to combat falsified, substandard, expired, or diverted medicines. She highlighted the strong support from the Ministry of Health, which has integrated the system into existing logistics frameworks and mandated red labels on all government medicines, with ongoing policy oversight.

LMHRA is tasked with leading the implementation, distributing security labels, operating verification platforms, and ensuring compliance through monitoring and enforcement. Importers, wholesalers, and manufacturers are required to affix blue LMHPP labels, keep accurate records, educate consumers, and reject suspicious products. Pharmacies and drug stores must ensure proper labeling, staff training, inspections, and community education. Hospitals and clinics are responsible for label verification and integrating LMHPP procedures into their inventory management.

Dr. Nagbe also emphasized the critical role of consumers in ensuring medicine safety. She encouraged individuals to look out for LMHPP labels, report any irregularities, use verification tools, and help raise awareness in their communities.

To support these efforts, LMHRA has developed a strategic plan to ensure all medicines entering the Liberian market are correctly labeled before distribution.

The Chief Medical Officer of Liberia, Dr. Catharine Thomas Cooper, highlighted the importance of the partnership between the Ministry of Health and LMHRA to address pressing health challenges, praising LMHRA’s work in combating the spread of substandard drugs.

The Chief Pharmacist, Dr. Joshua Peter, also acknowledged LMHRA’s vital role in aligning Liberia’s pharmaceutical standards with regional and international benchmarks.

Finally, Dr. Peter urged healthcare professionals to remain vigilant when handling medicines, stressing the importance of accuracy and diligence in safeguarding public health.
LMHRA, LMHPPP Hold Stakeholder Awareness on New Medicine Labeling

The Liberia Medicines & Health Products Regulatory Authority (LMHRA), together with the Liberia Medicines & Health Product Protection Program (LMHPPP), recently hosted an important awareness session for key health sector stakeholders.

The event took place at the Ministry of Health’s conference room in Congo Town on Thursday, July 10, 2025. It drew regulators, civil society representatives, and dedicated Liberians from across the country, all committed to strengthening pharmaceutical safety and public health.

The main purpose of the meeting was to introduce an innovative medicine labeling system aimed at clearly differentiating between donor-supplied medicines and those bought commercially. This measure intends to prevent the misuse of humanitarian supplies and safeguard the integrity of medicines circulating in Liberia.

Dr. Luke Bawo, Managing Director of LMHRA, emphasized that the project supports Liberia’s broader development goals of transforming healthcare delivery by 2029. He explained that the initiative is part of a comprehensive plan to bolster regulatory systems, improve access to essential medicines, expand health insurance coverage, and modernize healthcare infrastructure—key steps toward a healthier, more equitable Liberia.

“Our goal extends beyond increasing access,” Dr. Bawo stated. “It’s about ensuring the quality of medicines. Our citizens deserve a health system that is safe, effective, and trustworthy.”

Dr. Michael Chu Nepay, Program and Planning Coordinator at LMHRA, provided details about the new labeling system, highlighting its use of advanced technology for product verification and traceability. He introduced the Kulinda-Liberia platform, a sophisticated management system that employs smart security labels with embedded barcodes and color indicators, allowing real-time monitoring and instant validation of medicines’ authenticity.

“This initiative not only enhances public health protection for Liberia but also aims to serve as a model for neighboring West African countries,” Dr. Nepay remarked. “As the global community observes, LMHPPP’s approach could set a regional standard.”

The meeting was also intended to clarify stakeholders’ roles. Dr. Sandra Nagbe from the Program & Planning Unit described the Comprehensive Authentication and Traceability Program as a nationwide effort to combat falsified, substandard, expired, or diverted medicines. She highlighted the strong support from the Ministry of Health, which has integrated the system into existing logistics frameworks and mandated red labels on all government medicines, with ongoing policy oversight.

LMHRA is tasked with leading the implementation, distributing security labels, operating verification platforms, and ensuring compliance through monitoring and enforcement. Importers, wholesalers, and manufacturers are required to affix blue LMHPP labels, keep accurate records, educate consumers, and reject suspicious products. Pharmacies and drug stores must ensure proper labeling, staff training, inspections, and community education. Hospitals and clinics are responsible for label verification and integrating LMHPP procedures into their inventory management.

Dr. Nagbe also emphasized the critical role of consumers in ensuring medicine safety. She encouraged individuals to look out for LMHPP labels, report any irregularities, use verification tools, and help raise awareness in their communities.

To support these efforts, LMHRA has developed a strategic plan to ensure all medicines entering the Liberian market are correctly labeled before distribution.

The Chief Medical Officer of Liberia, Dr. Catharine Thomas Cooper, highlighted the importance of the partnership between the Ministry of Health and LMHRA to address pressing health challenges, praising LMHRA’s work in combating the spread of substandard drugs.

The Chief Pharmacist, Dr. Joshua Peter, also acknowledged LMHRA’s vital role in aligning Liberia’s pharmaceutical standards with regional and international benchmarks.

Finally, Dr. Peter urged healthcare professionals to remain vigilant when handling medicines, stressing the importance of accuracy and diligence in safeguarding public health.

14/07/2025

LMHRA, LMDC Shut Down Unauthorized Treatment Center In Monrovia

The Liberia Medicines & Health Products Regulatory Authority (LMHRA), in collaboration with the Liberia Medical & Dental Council (LMDC), has, with immediate effect, shut down an unauthorized treatment facility called “Worry No More About Heart Burn.” The center, owned and operated by Mr. Jackson Zumo, is located near Nancy Doe Market along Tubman Boulevard, 8th Street, Sinkor. The action was taken due to the center’s failure to adhere to basic medical standards, posing significant risks to public health.
The shutdown followed an inspection conducted on July 11, 2025, prompted by a tip-off and social media reports. A team led by LMHRA’s Head of Surveillance, Dr. Martu Fayiah Nyanti, visited the premises. During the investigation, the team uncovered serious concerns regarding the substandard quality of healthcare services being provided at the facility.
It was revealed that the center was operating illegally, offering treatment for conditions such as stroke, diabetes, brain ailments, and poor er****on, claims that are not supported by regulated medical practice or evidence-based medicine.
Speaking on behalf of LMHRA, Dr. Nyanti expressed deep concern over the management of the facility, emphasizing that such illegal operations could severely undermine Liberia’s healthcare system and endanger public safety.
Mr. Joseph Coleman, Clinical and Research Coordinator of the LMDC, also thanked the LMHRA team for their swift response, adding that this joint effort is a positive step toward ensuring a safer, more effective healthcare sector in Liberia.
Founded by Legislation in 2010, LMHRA is mandated by law to ensure that all health products imported into Liberia are safe and meet established regulatory standards, safeguarding public health across the nation.

07/07/2025

LMHRA Leadership Reinforces Commitment To Accountability
-Sign PMCS Contract to Meet 2026 Goals

In a significant step toward enhancing transparency and performance in Liberia’s public health sector, the Liberia Medicines & Health Products Regulatory Authority (LMHRA) has demonstrated its commitment to accountability by officially signing the Government’s Performance Management and Compliance System (PMCS) contract. The ceremony took place on Thursday, July 3, 2025, at the Executive Mansion, with LMHRA’s Managing Director, Dr. Luke L. Bawo, and Deputy Director, Dr. Patricia Quaye-Freeman, in attendance. Organized by the Office of the Director General of the Cabinet, the event establishes strategic benchmarks for LMHRA’s operations and objectives leading up to 2026.

This agreement reinforces LMHRA’s dedication to transparency, excellence in performance, and strict compliance with national governance standards. The PMCS initiative, a key reform introduced by President Joseph N. Boakai, aims to shift the public sector from merely promising results to achieving tangible, measurable outcomes—focusing on results-driven governance and citizen-centered service delivery.

As the agency responsible for ensuring the safety and efficacy of medicines and health products in Liberia, this contract marks a crucial milestone for LMHRA. It aligns the organization’s efforts with the broader “ARREST Agenda”—a presidential plan emphasizing accountability, responsiveness, efficiency, sustainability, and transparency across all government institutions.

The PMCS contract details specific objectives, targets, and deliverables for LMHRA by 2026. Performance indicators will concentrate on essential functions including drug registration, quality control processes, enforcement against counterfeit and substandard medicines, and overall operational effectiveness.

Since taking leadership in April 2024, Dr. Bawo and Dr. Quaye-Freeman have prioritized strengthening LMHRA’s capabilities. Dr. Bawo has outlined plans to upgrade staff skills, automate registration and assessment procedures, establish a traceability system, and develop a cutting-edge Quality Control Laboratory that meets international standards. The signing of the PMCS contract is expected to accelerate these strategic initiatives and ensure their formal implementation.

Launched in October 2024, the President’s Performance Management and Compliance System mandates all government agencies to formalize performance contracts. This initiative marks a new chapter of governance in Liberia, where public officials are held directly accountable for their performance and tangible results. Non-compliance with contractual benchmarks could lead to measures such as travel bans; as recent directives have shown following the conclusion of the 2024-2025 cycle.

By signing this contract, LMHRA’s leadership not only reaffirms its dedication to national reform but also maps out a clear trajectory for its future operations. This step aims to uphold professionalism, accountability, and excellence in the regulation of medicines and health products, thereby strengthening public trust and advancing improved health outcomes for all Liberians.

22/06/2025

LMHRA To Launch Comprehensive Testing Facility With Advanced Technology -Signs Agreement to Upgrade Quality Control Laboratory to Meet International Standards

(Monrovia-June 22, 2025): The Liberia Medicines & Health Products Regulatory Authority (LMHRA) is taking a significant step toward modernizing its Ultra-Modern Quality Control Laboratory to meet both ISO 17025 standards and the World Health Organization’s (WHO) Maturity-Level Three benchmarks. To achieve this, LMHRA has entered into a Memorandum of Understanding (MoU) with Quality Management Solutions (QMS) Company for the laboratory’s modernization.

During the official signing ceremony of the MoU, LMHRA Managing Director, Dr. Luke L. Bawo, described the move as “a historic development for the testing of medicines, health products, and other commodities in Liberia.” He emphasized that although the process was long and complex, including consultations with multiple government agencies such as the Ministry of Finance & Development Planning, the Ministry of Justice, the Public Procurement Concession Commission, and the Bureau of Concession, the prudent procedural steps were necessary for proper approval.

Dr. Bawo clarified that the MoU involves an investment ranging from US$3 million to US$5 million, with an eye toward profitability over time. The laboratory’s upgrade will enable testing across various sectors—medicines, health products, food, animal feeds, and petroleum products—serving Liberia and the wider region.

He explained that this collaboration is a Public-Private Partnership (PPP), noting that QMS is a profit-oriented entity. The agreement details how QMS will recoup its investment and how LMHRA will benefit financially, with a shared revenue model. He expressed optimism about establishing a state-of-the-art, comprehensive testing facility within months, recalling that the last such facility was at the National Drugs Service, which was destroyed by fire years ago.

Once operational, the new laboratory will surpass mere physical and visual testing, enabling LMHRA to take legal action against products that fail to meet standards. This effort aligns with the mandate outlined in the ARREST Agenda for Inclusive Development (AAID), which aims to enhance health regulation and increase testing coverage from 40 percent in 2025 to 95 percent by 2029.

Dr. Bawo praised the support of the LMHRA Board and expressed his confidence that the upgraded lab would restore Liberia’s testing capacity to international standards, fulfilling the vision of reaching ISO 17025 certification and WHO Maturity-Level Three.

QMS Operations Manager, Shoaib Mirza, also voiced his appreciation for the Liberian government’s support, emphasizing the company’s commitment to delivering reliable, world-class testing of medicines, food, petroleum, and other products. He highlighted QMS’s global experience working in countries like Turkey, Pakistan, Sri Lanka, and Dubai, alongside its recent regional capacity-building initiatives, including training with the United States Pharmacopeia in Ghana.

Mr. Mirza underlined that their shared goal is to establish an accurate, trustworthy, and fully traceable laboratory system that improves public health outcomes through scientific testing aligned with international standards. He reaffirmed QMS’s dedication to providing high-quality results that ensure safety and expressed enthusiasm for a fruitful partnership with LMHRA and Liberia’s stakeholders.

LMHRA Board Chairman, Dr. David Sumo, expressed his appreciation for the progress so far and indicated that additional elements of the agreement, including fee structures based on testing scope, would be formalized through an addendum. His vision remains to restore the lab to its former status, achieving ISO 17025 accreditation and WHO Maturity-Level Three.

QMS offers a wide range of specialized testing and quality management services tailored to the pharmaceuticals, food, and petroleum industries. These services include ensuring drug product consistency, shelf-life evaluation, microbial safety, nutritional analysis, contamination detection, and fuel performance testing— all helping to meet regulatory requirements and ensure consumer safety.

As Liberia’s national regulatory authority, LMHRA oversees licensing, registration, inspection, and monitoring of medicines and health products, working closely with international organizations like the WHO. Its role is critical in safeguarding public health by ensuring the availability of safe, effective, and high-quality medicines and other health-related products, and in strengthening the country’s regulatory system through capacity building and policy development.

16/06/2025

LMHRA Deputy Director of Pharmacovigilance Wraps Up Regional Training on Combating Substandard Medicines

(Monrovia, Liberia- June 16, 202): Dr. Teedoh E. Beyslow, Deputy Director of Pharmacovigilance at the Liberia Medicine and Health Products Regulatory Authority (LMHRA), has concluded a four-day regional workshop in Nairobi, Kenya.

The training focused on strengthening the capabilities of participating countries in detecting and managing substandard and falsified medicines and health products. Dr. Beyslow highlighted the critical role of vigilance in protecting public health, drawing on his extensive experience, including his previous position as Inspector General, which underscores his expertise in identifying counterfeit medications.

Research shows that approximately 14% of medicines in low- and middle-income countries are of poor quality, with Africa experiencing a rate of around 19%. The most impacted categories are antimalarials (19%) and antibiotics (12.4%).

Expressing his appreciation, Dr. Beyslow thanked the World Health Organization (WHO) and LMHRA for the opportunity to participate in this important training. He emphasized that the program enhances the authority’s capacity to verify pharmaceutical authenticity and called for continued personnel development within the inspectorate.

The workshop brought together numerous pharmaceutical experts committed to combating substandard drugs across the participating nations.

Founded by legislation in 2010, LMHRA is mandated by law to ensure that all health products imported into Liberia are safe for public use and meet regulatory standards.

16/06/2025

LMHRA Deputy MD Visits India To Strengthen Regulatory Collaboration And Policy Engagement

(Monrovia, Liberia — June 16, 2025): The Deputy Managing Director of the Liberia Medicines & Health Products Regulatory Authority (LMHRA), Dr. Patricia Quaye-Freeman, has departed Liberia for a four-day official visit to India, aimed at enhancing international cooperation on pharmacopoeia standards and regulatory systems. The visit, scheduled from June 16 to June 19, underscores Liberia’s commitment to strengthening global health security through improved regulatory partnerships.

India, renowned worldwide for its expertise in manufacturing generic medicines, continues to foster alliances with various nations to advance regulatory cooperation and promote mutual recognition of pharmacopoeial standards.

During her stay, Dr. Quaye-Freeman will participate in technical sessions focusing on pharmacopoeia standards, India’s regulatory environment, and successful public health initiatives. The international gathering involves policymakers and senior officials from 22 countries, including Liberia, Togo, Mali, Sierra Leone, Cameroon, Kenya, Botswana, Ethiopia, Jamaica, and others, along with delegates from the Caribbean Public Health Agency (CARPHA) and Canada. These discussions build on the momentum from the August 2024 Policymakers’ Forum, which saw numerous countries endorse the Indian Pharmacopoeia as a standard reference for drug regulation.

India’s role as a leader in the pharmaceutical sector is reinforced by its comprehensive pharmacopeia regulations, which are consistently aligned with global standards to ensure medicine safety and quality. Notably, over 70% of Liberia’s generic medicines are exported to highly regulated international markets. India’s focus on regulatory harmonization and standards adherence highlights its dedication to equitable access to quality medicines and global health equity. Dr. Quaye-Freeman will engage with Indian stakeholders and pharmaceutical leaders to advance LMHRA’s international collaborations and recognition efforts.

In addition to policy discussions, delegates will visit state-of-the-art laboratories in Ghaziabad, the Jan Aushadhi Kendra in Agra, and leading pharmaceutical and vaccine manufacturing facilities in Ahmedabad. These site visits aim to provide a firsthand look at India’s scientific and regulatory infrastructure, exemplifying its robust pharmaceutical ecosystem.

In Liberia, the LMHRA, established under the Medicines & Health Products Regulatory Authority Act of 2010, oversees the regulation of medicines and health products, ensuring their safety and high quality. The agency remains dedicated to combating the illegal distribution of expired medicines and strengthening international partnerships to protect public health.

India’s regulatory collaboration is further solidified by the country’s ongoing efforts to set global standards, with the Indian Pharmacopoeia playing a pivotal role. This partnership underscores India’s emerging position as a key player in the global health landscape and reflects its proactive stance in advancing public health worldwide.

Liberia Medicines & Health Products Regulatory Authority

01/08/2025

22/07/2025

15/07/2025

14/07/2025

07/07/2025

22/06/2025

16/06/2025

16/06/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	09:00 - 17:00
Tuesday	09:00 - 17:00
Wednesday	09:00 - 17:00
Thursday	09:00 - 17:00
Friday	09:00 - 17:00